SEARCH

SEARCH BY CITATION

References

  • 1
    Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000;356:12551259.
  • 2
    Hunziker T, Bruppacher R, Kuenzi UP, Maibach R, Braunschweig S, Halter F et al. Classification of ADRs: a proposal for harmonization and differentiation based on the experience of the Comprehensive Hospital Drug Monitoring Bern/St. Gallen, 1974–1993. Pharmacoepidemiol Drug Saf 2002;11:159163.
  • 3
    Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF et al. Revised nomenclature for allergy for global use: report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 2004;113:832836.
  • 4
    Pichler WJ. Delayed drug hypersensitivity reactions. Ann Intern Med 2003;139:683693.
  • 5
    Sheikh A, Alves B. Hospital admissions for acute anaphylaxis: time trend study. BMJ 2000;320:1441.
  • 6
    Gomes E, Cardoso MF, Praca F, Gomes L, Marino E, Demoly P. Self-reported drug allergy in a general adult Portuguese population. Clin Exp Allergy 2004;34:15971601.
  • 7
    Hung OR, Bands C, Laney G, Drover D, Stevens S, MacSween M. Drug allergies in the surgical population. Can J Anaesth 1994;41:11491155.
  • 8
    MacLaughlin EJ, Saseen JJ, Malone DC. Costs of beta-lactam allergies: selection and costs of antibiotics for patients with a reported beta-lactam allergy. Arch Fam Med 2000;9:722726.
  • 9
    Sade K, Holtzer I, Levo Y, Kivity S. The economic burden of antibiotic treatment of penicillin-allergic patients in internal medicine wards of a general tertiary care hospital. Clin Exp Allergy 2003;33:501506.
  • 10
    Robinson JL, Hameed T, Carr S. Practical aspects of choosing an antibiotic for patients with a reported allergy to an antibiotic. Clin Infect Dis 2002;35:2631.
  • 11
    Demoly P, Bousquet J. Drug allergy diagnosis work up. Allergy 2002;57(Suppl. 72):3740.
  • 12
    Mertes PM, Laxenaire MC, Lienhart A, Aberer W, Ring J, Pichler WJ et al. Reducing the risk of anaphylaxis during anaesthesia: guidelines for clinical practice. J Investig Allergol Clin Immunol 2005;15:91101.
  • 13
    Bochenek G, Niz Ankowska E, Szczeklik A. Testing for aspirin hypersensitivity. Allergy 2002;57:562565.
  • 14
    Benahmed S, Picot MC, Dumas F, Demoly P. Accuracy of a pharmacovigilance algorithm in diagnosing drug hypersensitivity reactions. Arch Intern Med 2005;165:15001505.
  • 15
    Brockow K, Romano A, Blanca M, Ring J, Pichler W, Demoly P. General considerations for skin test procedures in the diagnosis of drug hypersensitivity. Allergy 2002;57:4551.
  • 16
    Barbaud A, Goncalo M, Bruynzeel D, Bircher A. Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions. Contact Derm. 2001;45:321328.
  • 17
    Osterballe M, Scheller R, Stahl Skov P, Andersen KE, Bindslev-Jensen C. Diagnostic value of scratch-chamber test, skin prick test, histamine release and specific IgE in birch-allergic patients with oral allergy syndrome to apple. Allergy 2003;58:950953.
  • 18
    Wahlberg JE. Patch testing. In: LepoittevinJ, editor. Textbook of contact dermatitis, 3rd edn. Berlin: Springer-Verlag, 2001:435468.
  • 19
    Aberer W, Bircher A, Romano A, Blanca M, Campi P, Fernandez J et al. Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. Allergy 2003;58:854863.
  • 20
    Berrino AM, Voltolini S, Bignardi D, Fasce C, Minale P, Macchi M et al. Psychological aspects of drug intolerance. Allerg Immunol (Paris) 2005;37:9095.
  • 21
    Ring J, Messmer K. Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet 1977;1:466469.
  • 22
    Blaschke V, Fuchs T. Welche Zukunft hat die stationäre Allergologie? Allergologie 2003;26:255258.
  • 23
    Li Wan Po A, Kendall JM. Causality assessment of adverse effects when is re-challenge ethically acceptable? Drug Saf 2001;24:793799.
  • 24
    Messaad D, Sahla H, Benahmed S, Godard P, Bousquet J, Demoly P. Drug provocation tests in patients with a history suggesting an immediate drug hypersensitivity reaction. Ann Intern Med 2004;140:10011006.
  • 25
    Atanaskovic-Markovic M, Velickovic TC, Gavrovic-Jankulovic M, Vuckovic O, Nestorovic B. Immediate allergic reactions to cephalosporins and penicillins and their cross-reactivity in children. Pediatr Allergy Immunol 2005;16:341347.
  • 26
    Dance D, Basti S, Koch DD. Use of preservative-free lidocaine for cataract surgery in a patient allergic to “caines”. J Cataract Refract Surg 2005;31:848850.
  • 27
    Gall H, Kaufmann R, Kalveram CM. Adverse reactions to local anesthetics: analysis of 197 cases. J Allergy Clin Immunol 1996;97:933937.
  • 28
    Blanca M, Mayorga C, Torres MJ, Reche M, Moya MC, Rodriguez JL et al. Clinical evaluation of Pharmacia CAP System RAST FEIA amoxicilloyl and benzylpenicilloyl in patients with penicillin allergy. Allergy 2001;56:862870.
  • 29
    Himly M, Jahn-Schmid B, Pittertschatscher K, Bohle B, Grubmayr K, Ferreira F et al. IgE-mediated immediate-type hypersensitivity to the pyrazolone drug propyphenazone. J Allergy Clin Immunol 2003;111:882888.
  • 30
    Kleinhans M, Linzbach L, Zedlitz S, Kaufmann R, Boehncke WH. Positive patch test reactions to celecoxib may be due to irritation and do not correlate with the results of oral provocation. Contact Dermatitis 2002;47:100102.
  • 31
    Laking A, Vieluf D, Kiehn M, Ring J. Bedeutung von oralen Provokationstestungen bei Patienten mit Unverträglichkeitsreaktionen auf Analgetika und NSAR. Allergo J 1999;8:347355.
  • 32
    De Mello NR, Baracat EC, Tomaz G, Bedone AJ, Camargos A, Barbosa IC et al. Double-blind study to evaluate efficacy and safety of meloxicam 7.5 mg and 15 mg versus mefenamic acid 1500 mg in the treatment of primary dysmenorrhea. Acta Obstet Gynecol Scand 2004;83:667673.
  • 33
    Boussetta K, Ponvert C, Karila C, Bourgeois ML, Blic J, Scheinmann P. Hypersensitivity reactions to paracetamol in children: a study of 25 cases. Allergy 2005;60:11741177.
  • 34
    Dieppe PA, Ebrahim S, Martin RM, Juni P. Lessons from the withdrawal of rofecoxib. BMJ 2004;329:867868.